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Sulfated β-cyclodextrins (S-β-CDs) are useful excipients for improving the solubility of drugs. One such
formulation incorporating 5-fluorouracil (5-FU), termed FD(S), showed improved efficacy over 5-FU alone
in orthotopic carcinoma xenograft models. S-β-CDs have heparin-like anticoagulant properties, which may
have contributed toward the improved antitumor effect of FD(S). S-β-CDs have also been reported to modify
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membrane assay. S-β-CD does not alter proliferative endothelial cell sensitivity to 5-FU cytotoxicity. S-β-CD
alone and within FD(S) significantly inhibited angiogenesis by impeding endothelial cell migration, resulting
in the inhibition of tubule formation and hence new vasculature. In addition to the cytotoxic action of the
drug 5-FU, therapeutic inhibition of angiogenesis by S-β-CDs within FD(S) could potentially limit local
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ABSTRACT
Objective: Sulfated β-cyclodextrins (S-β-CDs) are useful excipients for improving the solubility of
drugs. One such formulation incorporating 5-fluorouracil (5-FU), termed FD(S), showed improved
efficacy over 5-FU alone in orthotopic carcinoma xenograft models [1]. S-β-CDs have heparin-like
anti-coagulant properties, which may have contributed to the improved anti-tumour effect of FD(S). Sβ-CDs have also been reported to modify a number of processes involved in angiogenesis. While the
anti-coagulant nature of S-β-CDs was established, the anti-angiogenic properties of S-β-CDs within
FD(S) were unknown.
Methods: The effect of S-β-CD and FD(S) proliferation and migration of endothelial cells in live-cell
kinetic assays, and the reorganisation of human umbilical vein endothelial cells into tubule structures in
vitro was assessed. Confirmation of the anti-angiogenic effect of S-β-CD was demonstrated using an ex
ovo chick embryo chorioallantoic membrane (CAM) assay.
Results: S-β-CD does not alter proliferative endothelial cell sensitivity to 5-FU cytotoxicity. S-β-CD
alone and within FD(S) significantly inhibited angiogenesis by impeding endothelial cell migration,
resulting in the inhibition of tubule formation and hence new vasculature.
Conclusions: In addition to the cytotoxic action of the drug 5-FU, therapeutic inhibition of
angiogenesis by S-β-CDs within FD(S) could potentially limit local invasion and metastases. This has
important implications for the exploitation of S-β-CDs for drug formulation improvements or for drug
delivery of anti-cancer biologics.
KEYWORDS
Angiogenesis, -cyclodextrin, 5-fluorouracil, endothelial cells, heparin, cancer.
1.

Introduction
Injectable formulations of 5-fluorouracil (5-FU) and its synergistic biomodulator Leucovorin™

(LV; calcium folinate) form the cornerstone of many current colorectal cancer (CRC) chemotherapy
regimens [2-3]. We previously reported the development of all-in-one injectable pH neutral
formulations of 5-FU and LV, which overcome the physical/chemical incompatibilities between 5-FU
and LV and otherwise prevent a single solution intravenous administration. This was achieved by
incorporating either polysulfated β-cyclodextrin (S-β-CD; 7–14 sulfate groups) or a hydroxypropyl βcyclodextrin (HP-β-CD) as excipients [4]. These formulations signficantly reduce phlebitis, thus
improving the tolerability of current intravenous 5-FU regimens whilst maintaining all cytotoxic
properties in vitro and in animal tumour models [1].
In addition to their solubilising properties, other significant benefits may also be gained through
the use of S-β-CDs in chemotherapy formulations as they are known to exhibit heparin-like anticoagulant activity [4-7]. Heparins are routinely used for the treatment of thromboembolic
complications in cancer patients, which are a result of the hyperactivation of the coagulation cascade
[8-9]. When used in conjunction with chemotherapeutics, heparins have been reported to improve the
survival outcomes for cancer patients in some [10-12] but not all trials which may be related to stage
and/or type of cancer [13]. This may be due to the fact that cancer metastasis process requires
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coagulation [14-15]. The heparins may also influence a number of cellular processes such as tumour
cell growth via inhibition of heparin binding growth factors, and angiogenesis, and thereby ultimately
affect cancer progression [8, 10].
Despite the potential benefits, a summary of animal model studies by Neirs et al. [12] concluded
that high doses of heparin administered at length are required to significantly reduce metastasis while
low doses of heparins given as part of short administration regimens were ineffective. Long-term
administration of high dose heparin is greatly limited as patients often experience hemorrhagic
complications due to the systemic inhibition of coagulation [16-19]. As S-β-CDs are associated with
reduced systemic anti-coagulant activity [6], these excipients not only provide a valuable alternative to
heparins but, when incorporated into chemotherapeutic drug formulations, may also improve the
survival outcomes for cancer patients.
We have previously reported that a 5-FU formulation incorporating 172 mg/mL of S-β-CD
(termed FD(S)) not only retained anti-coagulant properties [4] but was also shown to reduce tumour
growth more effectively than 5-FU/LV in an orthotopic human xenograft tumour model in mice [1]. It
is possible that the improved efficacy of FD(S) is due in part to the anti-coagulation properties of the Sβ-CD component of the formulation [4]. However, S-β-CDs have also been reported to modify a
number of processes involved in angiogenesis in a concentration-dependent manner [5, 20-21]. As the
maximum tolerated dose (MTD) of FD(S) represents a systemic concentration of S-β-CD of ~ 2 mM
per dose at which no bleeding problems were observed [1], it is conceivable that the improved anticancer effect of FD(S) compared to 5-FU/LV at the MTD is in part also due to the anti-angiogenesis
properties of S-β-CD.
Angiogenesis is a complex process, dependent on the interactions of various host and tumour cells
that involves endothelial cell (EC) adhesion, proliferation, migration and differentiation into tubule
structures [22-23]. As metastasis is the major cause of treatment failure in cancer patients [14-15], the
therapeutic inhibition of angiogenesis could therefore prove critical to the prevention of regrowth of
tumour masses treated with cytotoxic drug regimens and to limiting metastases [24]. To this end,
FD(S) may induce a synergistic effect, whereby the S-β-CD component inhibits angiogenesis and thus
metastasis in addition to the cytotoxic action of 5-FU/LV on tumour cells. The purpose of the current
study was thus to determine the effect of S-β-CD and FD(S) on the process of angiogenesis at a cellular
level, which involved analysis of the proliferation, migration and reorganisation of ECs into tubule
structures. Confirmation of this effect was also ascertained using an ex ovo chick embryo
chorioallantoic membrane (CAM) assay. As angiogenesis is a prognostic factor for metastatic cancer
[25], results demonstrating an anti-angiogenic effect of S-β-CD in FD(S) could inspire further
development of cytotoxic or other anti-cancer drugs incorporating this compound in their formulations.
2.

Materials and methods
2.1 Formulation preparation
Stock solutions of FD(S), S-β-CD and 2-(hydroxypropyl)-β-cyclodextrin (HP-β-CD) were

prepared as described previously [4]. The components of each formulation were dissolved in
endotoxin-free water (Sigma-Aldrich), and confirmed to be at pH 7.4 ± 0.1 before being passed
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through a 0.22 µM filter (Millipore) to sterilise. Pharmaceutical grade 5-FU solution (ONCO-TAIN®
5-Fluorouracil Injection, 50 mg/mL) was obtained from Mayne Pharma Pty. Ltd. (Salisbury South,
Australia). Leucovorin™ (LV) solution (Leucovorin Calcium Injection USP, 10 mg/mL) was obtained
from Hospira Australia Pty. Ltd. (Mulgrave, Australia). For 5-FU/LV, the components were prepared
immediately prior to use as described by Locke et al. [4]. Sulfated-β-cyclodextrin sodium salt (S-β-CD,
2206.5 g/mol, with approximately 9-12 sulfate groups per cyclodextrin molecule) and 2(hydroxypropyl)-β-cyclodextrin (HP-β-CD, 1540 g/mol) were obtained from Sigma-Aldrich.
2.2 Cell lines and culture conditions
The SV40 transformed EC (SVEC4-10) line and primary human vascular endothelial (HUV-ECC) line were purchased from American Type Culture Collection, distributed by Cryosite, Australia, and
cultivated as recommended by the supplier. SVEC4-10 cells retain the morphological and functional
characteristics of primary ECs but proliferate indefinitely without the specific growth factor
requirements of primary ECs [26]. Cells were routinely cultured in cell line specific media at 37 °C in a
95% humidified atmosphere, containing 5% CO2. SVEC4-10 cells were grown in DMEM (Invitrogen,
USA) supplemented with 5% (v/v) heat-inactivated fetal calf serum (FCS) (Sigma-Aldrich). The HUVEC-C cells were grown in HAMS/F12K nutrient mixture (Kaighn’s modification) containing 0.1
mg/mL unfractionated heparin (Sigma-Aldrich), 0.03 mg/mL endothelial cell growth supplement
(ECGS) (Sigma-Aldrich), 2.5 g/L sodium bicarbonate and supplemented with 10% (v/v) heatinactivated FCS (Sigma-Aldrich). All tissue culture flasks and cell assay plates used for the routine
culture of HUV-EC-C cells (passage 3 – 6) were coated overnight with a 1% (v/v) gelatin solution
(Sigma-Aldrich).
2.3 xCELLigence endothelial cell proliferation assays
The effect of 5-FU, FD(S) and S-β-CD on EC proliferation was determined using the
xCELLigence System (Roche Applied Science) in specialised 16-well E-16 plates. Following the
addition of 100 µL of cell culture media to the wells, the cell lines were seeded at 5000 cells/well in a
volume of 80 µL. The cells were allowed to settle for 30 min at room temperature before being
incubated at 37 °C for 24 h. Varying concentrations of the compounds in 20 µL sterile water were then
added and the plate was again incubated at 37 °C for 72 h. Comparisons were made to untreated cells
which received 20 µL of sterile water. Background wells containing media without cells were included.
The adhesion, spreading and proliferation of cells was measured as a dimensionless parameter termed
cell index (CI) in real-time. CI is derived from the relative change in measured electrical impedance,
whereby electrical impedance represents the presence and spread of adherent cells. Real-time data was
accumulated every 15 min and graphed using the RTCA-DP Software (version 1.2.1), supplied with
the xCELLigence System.
2.4 xCELLigence endothelial cell invasion/migration assays
The effect of S-β-CDs and FD(S) on SVEC4-10 and HUV-EC-C cell invasion/migration was
analysed with the xCELLigence System using specialised two-layer Cell Invasion and Migration plates
(CIM-plates), in which a porous membrane (pore size 8 μm) separates the upper and lower wells. Cell
culture media (160 µL) was added to the lower wells of the CIM-plates, omitting the test compounds.
The lower wells contained the chemotactic control of FCS-containing media or serum-free (SF) media
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for basal level invasion/migration. Following assembly of the CIM-plate, 25 µL of SF media was
dispensed into the upper wells and the plate was incubated at 37 °C for 1 h to allow for equilibration of
the membrane. For HUV-EC-C cells, the upper CIM-plate wells were pre-coated with 25 µL Geltrex
Basement Membrane Matrix gel (Invitrogen, USA) in order to allow cell adhesion and spreading.
During this time the cells (HUV-EC-C cells had been deprived of serum for the previous 12 h) were
harvested and resuspended in SF media, and then seeded into the upper wells at an optimised count of
40,000 cells/well in a volume of 90 µL. Varying concentrations of S-β-CDs and FD(S) that were
deemed non-toxic by cell proliferation assays, in 10 µL SF media were added into the upper wells
containing cell suspensions. Untreated cells received 10 µL SF media alone. The plate was incubated at
37 °C and the migration of cells across the membrane into the lower wells was measured as CI in realtime over 12 h. Real-time data was accumulated and graphed as described in Section 2.3.
2.5 In vitro angiogenesis inhibition assays
The effect of S-β-CD, alone and in the FD(S) formulation, on the degree of EC tubule formation
was examined using an in vitro Angiogenesis Assay Kit (Cayman Chemical Company, USA) in flatbottomed 24-well microplates coated with Geltrex Basement Membrane Matrix gel (Invitrogen, USA),
as a supportive matrix. Prior to cell seeding, a grid was drawn on the underside of the wells using a fine
marker pen to divide the area into quadrants and the wells were coated with 95 µL Geltrex. To solidify
the gel, the plate was warmed to 37 °C for 30 min. Cell suspensions were prepared in culture medium
in the absence or presence of 0.3 µM JNJ-10198409 angiogenesis inhibitor as a negative control or Sβ-CD or FD(S) at varying concentrations. Cells were seeded at an optimised density of 42,000
cells/cm² (80,000 cells/well) in a volume of 400 µL. Plates were incubated at 37 °C for 7 h to allow
tubule formation.
At the conclusion of incubation, cell morphology and the degree of tubule formation were
visualised using an inverted light microscope and inverted epifluorescence microscope with images
captured using a mounted digital camera (Nikon, Instruments Inc., USA) and mounted Leica DC500
camera (Leica Microsystems, Germany), respectively. Four photographs (4 × magnification) were
taken in each quadrant of duplicate treatment wells using an inverted light microscope, for manual
scoring of tubule formation, followed by four epifluorescence photographs (10 ×), for visualisation. For
manual scoring, multiple scorers blinded to the allocated treatment counted the number of fully
enclosed vacuoles formed by tubule branches in eight photographs per treatment, four from each
duplicated well; vacuoles that breached the edge of the photograph were not counted. Results were
analysed using a student’s unpaired t-test with p <0.05 considered significant. Cell and tubule network
morphology was also scored using a numerical ranking system from 0 to 3, adapted from the
Millicell® µ-Angiogenesis Inhibition Assay Protocol (Millipore, USA). Briefly, a score of 0 = mostly
undifferentiated cells, no/little tubule network or sprouting cells noted; 1 = sprouting of new tubules
visible with large pockets of undifferentiated cells between them; 2 = sprouting of new tubules visible
with small pockets of undifferentiated cells between them; 3 = expansive tubule networks with
consistently elongated cells. For fluorescent visualisation, a calcein (1000 ×) AM staining solution was
diluted 1:100 and added to the wells at a volume 40 µL/well. Cells were incubated at 37 °C for 30 min
to allow the calcein stain to develop.
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2.6 Ex ovo chick embryo chorioallantoic membrane (CAM) collagen onplant assay
To further examine the effect of S-β-CD on angiogenesis, an ex ovo chick embryo CAM collagen
onplant assay protocol was conducted, which utilises the highly vascularised CAM as an experimental
model capable of investigating angiogenesis [27]. Fertile Barter Brown Crossbreed chicken eggs were
obtained from Barter and Sons Hatchery (Luddenham, Australia). To initiate embryogenesis, the eggs
were placed into a rotary incubator at 37.8 °C and 60% relative humidity for 3 days. At embryonic day
3, the CAM was ‘dropped’ from the inside of the shell, as described in Storgard et al. (2004) [27]. The
shell was carefully cut open under sterile conditions using an engraving power tool, allowing for the
entire contents of the eggs to be transferred to pre-sterilised plastic weigh boats with slanted walls
(Lomb Scientific, Australia). The contents were covered with square Petri dish lids and the containers
were placed into a stationary incubator at 37.8 °C and 90% relative humidity for another 3 days to
allow the CAM to develop. At embryonic day 6, collagen onplants were prepared using autoclaved 4 ×
4 mm nylon mesh squares with 180 µm grid size (Sefar Inc., Australia). Onplants were assembled by
overlaying two mesh squares in Petri dishes, which were lined with parafilm and sterilised with
ethanol. Test compounds were diluted from stock solutions in 10 × PBS and added to neutralised 3
mg/mL collagen solutions prepared from rat-tail collagen (Sigma-Aldrich) as described in Deryugina et
al. (2008) [28]. The final collagen solutions contained either PBS alone (control), 0.01 µM JNJ10198409 or 0.3 mM S-β-CD, diluted from a 200 mM stock solution. This concentration of S-β-CD
was chosen because it falls within the range of concentrations that inhibit EC migration and is an
achievable systemic concentration after a MTD dose administration in mice [1]. The final collagen
solutions (30 µL) were placed on top of the mesh squares and the onplants allowed to polymerise at 37
°C for 1 h and then solidify at room temperature. The onplants were topically positioned on the CAM
in areas containing fine vascular networks. Individual embryos received four onplants, containing one
of each of the four treatments, in different quadrants of the embryo. Onplant-bearing embryos were
incubated for an additional 96 h at 37.8 °C and 90% relative humidity in a HERAcell stationary
incubator. At this time, the extent of vascularisation within the onplant was determined using a
stereomicroscope, with a Moticam 1000 live imaging camera attached (Motic, Canada).
3.

Results
3.1 S-β-CD does not alter EC proliferation or sensitivity to 5-FU cytotoxicity in vitro
During angiogenesis ECs proliferate to provide additional cells that will constitute the new vessel.

At this time, ECs have been activated into a proliferative state by the presence of growth factors. For
this reason, transformed SVEC4-10 cells were used as a model cell line for ECs under angiogenic
conditions.
To determine the effect of S--CD both alone and within FD(S) on EC proliferation over time and
to establish non-cytotoxic concentrations for subsequent assays, real-time live-cell kinetic assays were
used. In the absence of S-β-CD, SVEC4-10 cells grew exponentially up to 40 h after cell seeding then
reached a plateau (Fig. 1A, untreated). The addition of 20 mM S-β-CD 24 h after seeding caused an
initial steep, then continued decrease in CI values to zero impedance relative to the control within 48 h
of treatment (Fig. 1A). This indicates a complete loss of cells, which is suggestive of either a potent
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cytotoxic effect and/or loss of cell adhesion. At concentrations ≤ 4 mM, CI values were essentially
similar to that obtained with untreated cells (Fig. 1A), indicating that SVEC4-10 EC proliferation was
unaffected by S-β-CD at these concentrations. In other experiments, within 24 h after the addition of 10
mM S-β-CD, CI levels were partially reduced but recovered to that of untreated cells thereafter (data
not shown).
SVEC4-10 ECs treated with FD(S) encompassing a concentration range of 5-FU previously
shown to be cytotoxic after 72 h in a variety of cancer cell lines [4], displayed time-dependent
cytotoxic effects (Fig. 1B). S-β-CD concentrations within the FD(S) formulation corresponded to < 1
mM indicating that cytotoxic effects seen were due to the 5-FU component of the formulation. As
expected for 5-FU mediated cytotoxicity, dose-dependent cytotoxic effects were apparent 48 h
after compound addition with maximal effects obvious by 72 h post FD(S) treatment (Fig. 1B). An
IC50 value of ~ 20 µM was calculated by the RTCA-DP Software using the sigmoidal dose response
curve (r2 = 0.985). Graphpad Prism analysis of the data taken at 72 h post treatment from either the
xCELLigence system or from a standard endpoint assay routinely used for determination of cytotoxic
effects [4] revealed IC50 values of similar magnitude (i.e. 15 µM; Supplementary Fig. 1). That 5-FU
alone gave a similar IC50 value to FD(S) (14 vs 15.8 µM, Supplementary Fig. 1B), further confirms that
the S-β-CD component did not contribute to the cytotoxic action of FD(S).
The long population doubling time of HUV-EC-C cells (6 – 7 days) precluded testing the potential
cytotoxic effect of FD(S) as the cells did not proliferate under the time-frame and conditions of these
experiments (data not shown). S-β-CD over the concentration range 2.5 mM – 0.3 mM had no
stimulatory effect on HUV-EC-C cell proliferation (data not shown).
3.2 S-β-CD alone and within FD(S) inhibits EC migration
The migratory function of ECs is essential for angiogenesis. The effect of S-β-CD on SVEC4-10
EC migration was thus determined at concentrations that were not anti-proliferative/cytotoxic (< 4
mM). S-β-CD over the concentration range (4 mM - 1.25 μM), inhibited the migration of SVEC4-10
ECs towards FCS as the chemoattractant in the lower chambers (Fig. 2A, control). At the highest
concentration of S-β-CD CI values were essentially equivalent to basal CI values (serum-free media in
the lower chambers). The inhibitory effect of S-β-CDs on SVEC4-10 migration was slightly reduced at
the lower concentrations (0.8 mM – 1.28 M), with no apparent dose response in this range (Fig. 2A).
The reason for this lack of dose-dependency is unclear. SVEC4-10 EC migration was mildly stimulated
(~ 12% above the level of the positive control) at very low-range concentrations of S-β-CDs (≤ 0.5
M) (data not shown). The inhibitory effect of S-β-CD on SVEC4-10 cell migration was
uncompromised within FD(S) (equivalent S-β-CD concentration range 4 mM – 1.25 M) (Fig. 3B).
The FD(S) has no cytotoxic effect within the timeframe of the migration assays (12 h) (refer to Fig.
1B) and so this effect is attributed to the S-β-CD component.
At 20 M, 200 M and 2 mM, S-β-CD alone completely inhibited the migration of serumdeprived HUV-EC-C cells towards FCS as the chemoattractant as the observed CI values were
equivalent to basal CI values (Fig. 3A). HUV-EC-C cell migration was also inhibited by FD(S)
containing equivalent concentrations of S-β-CD (Fig. 3B), though 20 and 200 M S-β-CD in FD(S)
was not as efficient as 20 and 200 M S-β-CD alone. At 2 mM S-β-CD in FD(S), migration was
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completely inhibited (Fig. 3B). Thus, incorporation of S-β-CD in FD(S) did not compromise the
inhibition of HUV-EC-C cell invasion and migration. The potential requirement for an invasion step
through the GELTREX coating on membranes necessary for HUV-EC-C cell attachment and spreading
in the assay chambers (not required for SVEC4-10 ECs), prior to migration may have accounted for the
small concentration effect difference between the HUV-EC-C and SVEC4-10 ECs.
3.3 S-β-CD inhibits spontaneous tubule formation by HUV-EC-C cells at therapeutic doses of
FD(S)
The culture of ECs on a supportive matrix with growth factors results in morphological changes
and the formation of tubule structures that replicate vasculature, a phenomenon known as spontaneous
angiogenesis [29]. This was demonstrated by the formation of expansive tubule networks (morphology
score = 3) when HUV-EC-C cells were grown on Geltrex with growth factor containing media (Fig.
4A; media control). Incubation of HUV-EC-C cells in the presence of the angiogenisis inhibitor control
JNJ-10198409 reduced the formation of tubule networks with small pockets of undifferentiated cells
observed between tubule branches (morphology score = 2) (Fig. 4B).
At 15.6 µM S-β-CD alone (Fig. 4C) and in FD(S) (Fig. 4D), HUV-EC-C cell morphology was
similar to that after JNJ-10198409 treatment, with pockets of undifferentiated cells between tubule
branches observed, and were both scored a value of 2 for tubule network morphology. Manual scoring
of fully enclosed vacuoles formed by tubule branches however, found no significant differences (p >
0.1) compared to media control. Cells remained undifferentiated with no tubule network formation
evident (morphology score = 0) after treatment with 1.56 mM S-β-CD alone (Fig. 5E) and in FD(S)
(Fig. 5F). This represented significant inhibition of spontaneous angiogenesis as vacuoles formation
was reduced by 96.1% (p < 0.0001) and 97.9% (p < 0.0001), respectively, compared to the media
control as determined by manual scoring. This inhibitory effect was due to the S-β-CD component of
FD(S) since an equivalent concentration of non-sulfated HP-β-CD, either alone or incorporated into a
separate 5-FU formulation termed FD(HP) [4], did not affect the degree of tubule formation relative to
the media control (Supplementary Fig. 2). Within the timeframe of these experiments (7 h), changes in
cell numbers due to treatment with 1.56 mM S-β-CD were not expected (see above).
3.4

S-β-CD prevents the formation of new vasculature ex ovo

The ex ovo chick embryo CAM collagen onplant assay was used to confirm the inhibitory effect
of S-β-CD on angiogenesis. PBS-containing control onplants did not induce the advancement of fine
vessels towards the onplant after 4 days as expected (Fig. 5A), though fine vessels branching from preexisting major vessels within the onplant site were observed. Onplants containing the inhibitory control
JNJ-10198409 prevented the formation of new fine vasculature over the 4 day treatment period and a
fine vessel avascular zone was evident within the onplant area (Fig. 5B). Onplants containing 0.3 mM
S-β-CDs also prevented the formation of new vasculature over the 96 h treatment period (Fig. 5C).
Observations at higher magnification revealed a 2-3 mm avascular region free of fine blood vessels
within the onplant area (Supplementary Fig. 3).
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4.

Discussion
The results of the current study confirm the inhibitory potential of S-β-CD alone on angiogenesis

in vitro and ex ovo and, importantly, that these anti-angiogenesis properties are maintained in FD(S).
At and below concentrations of S-β-CD that are achievable after systemic administration of FD(S)
doses that reduce tumour growth (< 2mM S-β-CD) [1], FD(S) dramatically inhibited spontaneous
tubule formation of HUV-EC-C cells in vitro in a dose-dependent manner. This effect appears
mediated via inhibition of invasion/migration of differentiated ECs. The lack of effect of a non-sulfated
β-CD on in vitro angiogenesis as well as EC migration (data not shown) confirmed the necessity of
sulfate groups for the anti-angiogenic activity of S-β-CDs [5, 21]. Water soluble sulfated cyclodextrins
show low systemic toxicity in animals [6], and high concentrations of S-β-CD (up to 1 mM) are not
cytotoxic against a variety of human carcinoma cell lines [4] or human vascular smooth muscle cells
[20]. This was confirmed for the transformed EC cell line SVEC4-10 at concentrations of S-β-CD ≤ 4
mM. As reported for carcinoma cell lines [4], FD(S) encompassing these non-toxic S-β-CD
concentrations was cytotoxic agaisnt SVEC4-10 ECs, reflective of the antimetabolite activity of 5-FU
achieved in proliferative cells [4]. Thus, together with the potential anti-coagulant effects of S-β-CD in
the metastatic process, we propose that the beneficial effect of FD(S) over 5-FU alone in tumour
models was due to the synergistic action of: a) 5-FU toxicity against proliferating tumour cells as well
as ECs stimulated to proliferate during the angiogenic process, and b) the immediate antiinvasive/migratory effect of S-β-CD on both differentiated and undifferentiated ECs. A detailed study
to examine all of these effects of FD(S) in tumour models is now warranted.
Angiogenesis involves the rearrangement of localised ECs to form tubule structures [30],
following the recruitment and migration of ECs by chemotaxis [31-32]. The inhibitory effect on in
vitro EC tubule formation and migration of S-β-CDs is possibly linked to the ability of S-β-CDs to
interact with and inhibit the activity of several key growth factors present in the FCS [33], including
bFGF, PDGF and TGF-β [20, 34]. Low molecular weight heparins and S-β-CDs alike bind with high
affinity to bFGF [20, 35-36] and, despite exhibiting no cytotoxic potential, S-β-CDs are able to inhibit
smooth muscle cell proliferation induced by bFGF [36]. It is therefore proposed that the cellular
processes mediated by these growth factors, in particular EC migration and differentiation are affected
by S-β-CD and these are not substantially diminished by FD(S). In this manner, S-β-CD appears to
mimic low molecular weight heparins, which inhibit bFGF and VEGF mediated angiogenesis by
preventing these growth factors from binding to their respective receptors on ECs [9, 12, 37].
We also examined the effect of S-β-CDs on angiogenesis in an ex ovo chick embryo CAM model
as there has been conflicting data in the literature regarding the pro/anti-angiogenic effects in various
animal models. For example, in an embryonic chick CAM model, β-CD tetradecasulfate administered
in conjunction with a steroid was found to inhibit angiogenesis at 100 to 1000 times the effectiveness
of a heparin and steroid combination on a per weight basis [5]. However in a rabbit cornea model, CD tetradecasulfate, when administered alone at very low concentrations (15 g/mm3; ~ 6 M),
stimulated blood vessel growth and density [5]. Using a subcutaneous plastic sponge model in mice,
Strauss et al. [21] demonstrated a dose dependent effect after intraperitoneal administration of S-β-CDs
alone on capillary density, with very low doses (200 ng/mouse; ~0.06 M) apparently promoting
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angiogenesis while “high” doses (20 g/mouse; ~6 M) reduced vessel index in the sponges. We found
that collagen onplants in chick embryo CAMs containing S-β-CDs prevented the formation of new
vasculature within the onplant site, creating an avascular regression zone free of blood vessels. Ribatti
et al. [38], who examined angiogenesis on the CAM in response to an anti-bFGF antibody, defined
inhibition to be a region around the onplant with no vascular reaction or, where

pre-existing

vasculature is present, it remains unresponsive to treatments. The latter was observed with onplants
containing S-β-CD and JNJ-10198409 (Fig. 5). Yadav et al. [39], who investigated the anti-angiogenic
effect of curcumin in complexation with nonsulfated β-CDs, defined angiogenesis inhibition as a zone
of avascularity, which can be 2-6 mm in diameter, as a result of vessel occlusion or regression. Zones
of avascularity observed in response to S-β-CDs and JNJ-10198409 were approximately 2-3 mm in
diameter within the central area of the onplant.
Prolonged IV administration of S-β-CDs was found to be necessary to produce sustained
inhibition of intimal hyperplasia [34], which is a vascular remodelling and repair process in response to
the injury of vascular walls (Wu et al. 2009). Intimal hyperplasia is similar to the metastatic cascade as
it involves stimulation of the coagulation cascade, EC and SMC migration and proliferation, and is
dependent upon angiogenic growth factors and selectin interactions [34, 40]. The requirement of
prolonged IV administration of S-β-CDs may be related to the fact that IV-administered β-CDs are
eliminated rapidly from circulation [41]. Continuous administration of S-β-CDs may therefore be
required and, favourably, S-β-CDS possess a reduced anti-coagulant activity as compared to heparins
[6], allowing them to be administered at higher dosages [20, 42]. Importantly, FD(S) allows for the
simultaneous IV-administration of all components, 5-FU, LV and S-β-CDs, and may improve the
outcome for cancer patients by ensuring the continual administration of S-β-CDs at high, yet tolerable
concentrations.
Finally, the inclusion of therapeutic doses of S-β-CDs in anti-cancer drug formulations, such as
FD(S), offers the potential to limit local invasion and metastases, through the inhibition of
angiogenesis, as well as to reduce tumour growth. Together with its useful anti-coagulant properties, Sβ-CD as a component in anti-cancer drug formulations should be exploited for the development of a
new generation of dual action therapeutics with potential for improved survival outcomes for cancer
patients.
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List of Figures
Fig. 1 The effect of (a) S-β-CD and (b) FD(S) on SVEC4-10 cell proliferation. Cells were
cultivated for 24 h before the addition of S-β-CD or FD(S) at the concentrations shown, or media only
(untreated controls; orange line) and monitored over 72 h in real-time using an xCELLigence RTCA
DP System. The electronic readout of cell sensor impedance is displayed continuously as the Cell
Index (CI) normalised to the compound addition timepoint (indicated by vertical dotted line). Values
shown are means + SD of duplicate treatments of a representative experiment.
Fig. 2 The effect of (a) S-β-CD and (b) FD(S) on the migration kinetics of SVEC4-10 ECs by
continuous monitoring of live-cell migration. Cell suspensions were prepared in SF media and placed
in the upper wells of CIM-plates in the absence (control/untreated; orange line) or presence of S-β-CD
alone (a) or S-β-CD and 5-FU in FD(S) (b) at the concentrations shown and allowed to migrate
towards 5% FCS in the lower wells over 12 h. Controls containing SF media in the lower wells (basal;
green line) confirm the negligible levels of cell migration in the absence of a chemotatic stimulus. The
electronic readout of cell sensor impedance, which indicates the presence of cells on the underside of
the membrane through which the cells migrated, is displayed continuously as the Cell Index (CI).
Values shown are means + SD of duplicate treatments of a representative experiment.
Fig. 3 The effect of (a) S-β-CD and (b) FD(S) on the invasion/migration kinetics of HUV-EC-C
cells by continuous monitoring of live-cell migration. Serum-starved cells were resuspended in SF
media and placed in the upper wells of Geltrex-coated CIM-plates in the absence (control/untreated;
orange line) or presence of S-β-CD alone (a) or S-β-CD (mM) and 5-FU (g/mL) in FD(S) (b) at the
concentrations shown and allowed to migrate towards 10% FCS in the lower wells over 12 h. Controls
containing SF media in the lower wells (basal; green line) confirm the negligible levels of cell
migration in the absence of a chemotatic stimulus. The electronic readout of cell sensor impedance is
displayed continuously as the Cell Index (CI). Values shown are means + SD of duplicate treatments of
a representative experiment.
Fig. 4 HUV-EC-C cell in vitro angiogenesis inhibition assays. Cells were incubated on Geltrex for
7 h at 37 °C with the addition of (a) media only, (b) 0.3 µM JNJ-10198409 angiogenic inhibitor, (c)
15.6 µM S-β-CD, (d) 15.6 µM S-β-CD in FD(S) (equivalent to 3 g/mL or 23 M 5-FU), (e) 1.56 mM
S-β-CD and (f) 1.56 mM S-β-CD in FD(S) (equivalent to 300 g/mL or 2.3 mM 5-FU). Fluorescent
images of cells stained with calcein AM staining solution are shown as viewed under the microscope at
100X magnification. Bright field images (not shown) were used only for manual scoring and
morphology scoring.
Fig. 5 Ex ovo chick embryo chorioallantoic membrane (CAM) collagen onplant assay
Representative macroscopic observations of the vascular response of ex ovo chick embryo CAMs to
collagen onplants containing (a) PBS only, (b) 0.01 µM JNJ-10198409 and (c) 0.3 mM S-β-CD.
Solidified onplants (boxed) were placed on the embryonic CAM in areas of fine vessel networks at
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embryonic day 6 (corresponds to treatment Day 0), with one onplant of each treatment positioned in
different quadrants per embryo. For each onplant, stereomicroscope images (8X magnification) were
taken at Day 0 and 96 h (Day 4) later.
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Supplementary Figure 1 Legend:
A. Data taken from xCELLigence output (Fig 1B) at 72 h post FD(S) addition for SVEC4-10
ECS. Values shown are mean, n = 2, of a representative experiment. The relative IC50, defined as the
concentration of 5-FU causing 50% inhibition of cell proliferation, was calculated to be 1954 ng/ml (15
M).
B. Comparison of cytotoxic effect of 5-FU versus FD(S) on SVEC4-10 ECs 72 h after treatment.
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Determined using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS, Promega), as
described previously.1 Cells were seeded into 96-well plates (104 cells/well) and grown for 24 h prior to
treatment with serial dilutions of FD(S) or 5-FU for 72 h. The absorbance at 490 nm was measured
using a Spectromax® 250 UV plate reader employing Softmax Pro® software (Molecular Devices,
USA). Values shown are mean +/-SEM, n = 3, of a representative experiment.
For both A and B: data was analysed using a sigmoidal dose-response using the variable slope
parameter to determine IC50 values (GraphPad Prism, Version 5.0). Data was normalised to control (no
drug - denoted as equivalent to 1 ng/mL) = 100% proliferation.
The relative IC50, defined as the concentration of 5-FU causing 50% inhibition of SVEC4-10 EC
proliferation, was calculated to be 1869 ng/mL (14 M) for 5-FU and 2057 ng/mL (15.8 M) for 5-FU
in FD(S).
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20: p. 822‐831.
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